DDInter909 DDInter624
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Imatinib {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Imatinib {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Imatinib {u} (Compound) upregulates {v} (Gene) SATB1
SATB1 {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Imatinib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Imatinib {u} (Compound) upregulates {v} (Gene) SATB1
SATB1 {u} (Gene) is regulated by {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Imatinib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Imatinib {u} (Compound) upregulates {v} (Gene) SATB1
SATB1 {u} (Gene) regulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Imatinib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Imatinib (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Imatinib (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Imatinib (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is regulated by TBX2 (Gene) and TBX2 (Gene) is upregulated by Efavirenz (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Imatinib (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) regulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Efavirenz (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)